TY - JOUR
T1 - Urinary N-terminal pro–B-type natriuretic peptide as a biomarker for cardiovascular events in a general Japanese population
T2 - the Hisayama Study
AU - Yamasaki, Keisuke
AU - Hata, Jun
AU - Ide, Tomomi
AU - Nagata, Takuya
AU - Sakata, Satoko
AU - Yoshida, Daigo
AU - Honda, Takanori
AU - Hirakawa, Yoichiro
AU - Nakano, Toshiaki
AU - Kitazono, Takanari
AU - Tsutsui, Hiroyuki
AU - Ninomiya, Toshiharu
N1 - Funding Information:
This study was supported in part by Grants-in-Aid for Scientific Research A (JP16H02692), B (JP17H04126, JP18H02737, and JP19H03863), C (JP18K07565, JP18K09412, JP19K07890, JP20K10503, and JP20K11020), Early-Career Scientists (JP18K17925), and Research Activity Start-up (JP19K23971) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; by Health and Labour Sciences Research Grants of the Ministry of Health, Labour and Welfare of Japan (20FA1002); and by the Japan Agency for Medical Research and Development (JP20dk0207025, JP20km0405202, and JP20fk0108075).
Funding Information:
Hiroyuki Tsutsui reports grants and personal fees from Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Nippon Boehringer Ingelheim Co., Ltd.; grants from IQVIA Services Japan, Omron Healthcare, and MEDINET Co., Ltd.; and personal fees from AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Novartis Pharma K.K., Bayer Yakuhin, Ltd., Pfizer Japan Inc., Bristol-Myers Squibb Company, Kowa Company, Limited, and Nippon Rinsho, outside the submitted work. The other authors declare that they have no competing interests.
Funding Information:
We thank the residents of the town of Hisayama and the staff of the Division of Health of Hisayama for their cooperation in this study. In addition, we thank Professor Yoshinao Oda, Professor Toru Iwaki, and their colleagues in the Department of Anatomic Pathology and Department of Neuropathology, Graduate School of Medical Sciences, Kyushu University, who provided crucial insight into the autopsy findings. The statistical analyses were carried out using the computer resources offered under the category of General Projects by the Research Institute for Information Technology, Kyushu University.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Background: Epidemiological evidence has shown that serum N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations, a diagnostic biomarker for heart failure, are positively associated with cardiovascular risk. Since NT-proBNP in serum is excreted in urine, it is hypothesized that urinary NT-proBNP concentrations are correlated with serum concentrations and linked with cardiovascular risk in the general population. Methods: A total of 3060 community-dwelling residents aged ≥ 40 years without history of cardiovascular disease (CVD) were followed up for a median of 8.3 years (2007–2015). Serum and urinary concentrations of NT-proBNP at baseline were compared. The hazard ratios (HRs) and their 95% confidence intervals (CIs) for the association between NT-proBNP concentrations and the risk of developing CVD were computed using the Cox proportional hazards model. Results: The median values (interquartile ranges) of serum and urinary NT-proBNP concentrations at baseline were 56 (32–104) pg/mL and 20 (18–25) pg/mL, respectively. There was a strong quadratic correlation between the serum and urinary concentrations of NT-proBNP (coefficient of determination [R2] = 0.72): urinary concentrations of 20, 27, and 43 pg/mL were equivalent to serum concentrations of 55, 125, and 300 pg/mL, respectively. During the follow-up period, 170 subjects developed CVD. The age- and sex-adjusted risk of CVD increased significantly with higher urinary NT-proBNP levels (P for trend < 0.001). This association remained significant after adjustment for traditional cardiovascular risk factors (P for trend = 0.009). The multivariable-adjusted risk of developing CVD almost doubled in subjects with urinary NT-proBNP of ≥ 43 pg/mL as compared to those with urinary NT-proBNP of ≤ 19 pg/mL (HR 2.07, 95% CI 1.20–3.56). Conclusions: The present study demonstrated that urinary NT-proBNP concentrations were well-correlated with serum concentrations and were positively associated with cardiovascular risk. Given that urine sampling is noninvasive and does not require specially trained personnel, urinary NT-proBNP concentrations have the potential to be an easy and useful biomarker for detecting people at higher cardiovascular risk.
AB - Background: Epidemiological evidence has shown that serum N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations, a diagnostic biomarker for heart failure, are positively associated with cardiovascular risk. Since NT-proBNP in serum is excreted in urine, it is hypothesized that urinary NT-proBNP concentrations are correlated with serum concentrations and linked with cardiovascular risk in the general population. Methods: A total of 3060 community-dwelling residents aged ≥ 40 years without history of cardiovascular disease (CVD) were followed up for a median of 8.3 years (2007–2015). Serum and urinary concentrations of NT-proBNP at baseline were compared. The hazard ratios (HRs) and their 95% confidence intervals (CIs) for the association between NT-proBNP concentrations and the risk of developing CVD were computed using the Cox proportional hazards model. Results: The median values (interquartile ranges) of serum and urinary NT-proBNP concentrations at baseline were 56 (32–104) pg/mL and 20 (18–25) pg/mL, respectively. There was a strong quadratic correlation between the serum and urinary concentrations of NT-proBNP (coefficient of determination [R2] = 0.72): urinary concentrations of 20, 27, and 43 pg/mL were equivalent to serum concentrations of 55, 125, and 300 pg/mL, respectively. During the follow-up period, 170 subjects developed CVD. The age- and sex-adjusted risk of CVD increased significantly with higher urinary NT-proBNP levels (P for trend < 0.001). This association remained significant after adjustment for traditional cardiovascular risk factors (P for trend = 0.009). The multivariable-adjusted risk of developing CVD almost doubled in subjects with urinary NT-proBNP of ≥ 43 pg/mL as compared to those with urinary NT-proBNP of ≤ 19 pg/mL (HR 2.07, 95% CI 1.20–3.56). Conclusions: The present study demonstrated that urinary NT-proBNP concentrations were well-correlated with serum concentrations and were positively associated with cardiovascular risk. Given that urine sampling is noninvasive and does not require specially trained personnel, urinary NT-proBNP concentrations have the potential to be an easy and useful biomarker for detecting people at higher cardiovascular risk.
UR - http://www.scopus.com/inward/record.url?scp=85104295141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104295141&partnerID=8YFLogxK
U2 - 10.1186/s12199-021-00970-0
DO - 10.1186/s12199-021-00970-0
M3 - Article
C2 - 33845756
AN - SCOPUS:85104295141
SN - 1342-078X
VL - 26
JO - Environmental health and preventive medicine
JF - Environmental health and preventive medicine
IS - 1
M1 - 47
ER -